New combo therapy aims to beat tough skin cancers without major surgery

NCT ID NCT07251413

First seen Jan 05, 2026 · Last updated May 05, 2026 · Updated 20 times

Summary

This study is for people with high-risk basal cell skin cancer that is hard to treat with surgery alone. It tests a combination of an immunotherapy drug (cemiplimab), a topical cream (imiquimod), and laser therapy given before surgery to shrink tumors and lower the chance of the cancer coming back. The goal is to improve cure rates while reducing the need for disfiguring surgery. About 18 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital Clínic de Barcelona. Carrer de Villarroel, 170, L'Eixample

    RECRUITING

    Barcelona, Barcelona, 08036, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Miguel Servet de Zaragoza. P.º de Isabel la Católica, 1-3

    RECRUITING

    Zaragoza, Zaragoza, 5009, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Ramón y Cajal. M-607, Km. 9, 100, Fuencarral-El Pardo,

    RECRUITING

    Madrid, Madrid, 28034, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitario Dexeus - Grupo Quirónsalud. Carrer de Sabino Arana, 19 Ed, Distrito de Les Corts

    RECRUITING

    Barcelona, Barcelona, 08028, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.